Endios Bio raised an undisclosed amount of funding to advance its first-in-class PEG10-targeted therapeutics for amyotrophic lateral sclerosis (ALS) and related neurodevelopmental disorders.
Endios Bio raised an undisclosed amount of funding to advance its first-in-class PEG10-targeted therapeutics for amyotrophic lateral sclerosis (ALS) and related neurodevelopmental disorders.